Kiniksa Pharmaceuticals International PLC (NAS:KNSA)

$ 22.35 0.74 (3.42%) Market Cap: 1.59 Bil Enterprise Value: 1.33 Bil PE Ratio: 203.18 PB Ratio: 3.66 GF Score: 62/100

Q1 2024 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Apr 23, 2024

$17.68 (+3.42%)

Earnings
Q4 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Feb 28, 2024

$20.36 (-2.54%)

Earnings
Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Oct 31, 2023

$15.25 (-2.74%)

Earnings
Q2 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Jul 25, 2023

$19.48 (+30.39%)

Earnings
Kiniksa Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
May 02, 2023

$12.59 (+14.66%)

Earnings
Q4 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Feb 28, 2023

$12.86 (-3.45%)

Earnings
Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Kiniksa Pharmaceuticals Ltd at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022
Q3 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Nov 01, 2022

$12.8 (+12.08%)

Earnings
Q2 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Aug 03, 2022

$10.68 (+7.12%)

Earnings
Q1 2022 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
May 03, 2022

$10.11 (+7.44%)

Earnings
Q4 2021 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Feb 22, 2022

$10.62 (-0.93%)

Earnings
Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Q3 2021 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Nov 01, 2021

$12.73 (+22.52%)

Earnings
Q2 2021 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript
Aug 03, 2021

$13.69 (-15.65%)

Earnings
Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Kiniksa Pharmaceuticals Ltd FDA Approval of ARCALYST (rilonacept) for Recurrent Pericarditis Conference Call Transcript
Mar 18, 2021
Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Kiniksa Pharmaceuticals Ltd Rilonacept Analyst Day Transcript
Sep 29, 2020
Kiniksa Pharmaceuticals Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Kiniksa Pharmaceuticals Ltd Annual Shareholders Meeting Transcript
Jun 30, 2020
Kiniksa Pharmaceuticals, Ltd. - Special Call Transcript
Jun 29, 2020
Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 11, 2019
Kiniksa Pharmaceuticals Ltd at Barclays Global Healthcare Conference Transcript
Mar 12, 2019

Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript

Oct 31, 2023 / 12:30PM GMT

Release Date Price: $15.25 (-2.74%)

Transcript 10-Q8-K

Operator

Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. And I would now like to hand the conference over to your speaker today, Ms. Rachel Frank. Please go ahead.

Rachel Frank

Kiniksa Pharmaceuticals, Ltd. - Associate Director of IR

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa Call to discuss our third quarter 2023 financial results and recent portfolio execution. Press release highlighting these results can be found on our website under the Investors section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our commercial execution. John Paolini, our Chief Legal Officer, will provide a KPL-404 forum review; and Mark Ragosa, our Chief Financial Officer, who will review our third quarter 2023 financial results. And finally, Sanj will return for closing remarks and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.